Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvanted QVLP Influenza Vaccine in Adults 65+
NCT04622592Phase 2Completed
- Sponsor
- Medicago Inc.
- Start
- Nov 2020
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza (8 arms), sponsored by Medicago Inc. Primary endpoints: Geometric Mean Titers of Hemagglutination Inhibition Antibody Response at Day 0, Percentage of Participants with Seroconversion Measured by HI Antibody Response at Day 28 and 7 more. Started Nov 2020; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT04622592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622592.